Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary
May 9, 2023
Earnings Call Speaker Segments
Vivian Wu
executiveThanks, Crystal, and good afternoon, everybody. We appreciate you being with us today; joining us on this call are our President and CEO, Howard Robin; our Chief of Research and Development, Dr. Jonathan Zalevsky; our Chief Medical Officer, Dr. Mary Tagliaferri; and Sandra Gardiner, who is serving as our acting Chief Financial Officer. During this call, we anticipate delivering forward-looking statements about our business, including statements about the therapeutic potential of and future development plans for drug candidates and research programs, when clinical studies will begin and when clinical data for our drug candidates will become available, the timing of and plans for upcoming clinical data presentations, the formation — future development plans or success of our collaboration arrangements, what we expect following our corporate restructuring and reorganization, financial guidance, and certain other statements about the future of our business. Since forward-looking statements concern the future, they carry uncertainties and risks that are hard to predict, and many of them lie beyond our control. Our actual results could differ materially from these statements. Significant risks and uncertainties appear in our Form 10-K filed on February 28, 2023, which you can find at sec.gov; we assume no obligation to update any of these forward-looking statements, whether because of new information, future developments or otherwise. A webcast of this call will be accessible on the IR page of Nektar’s website at nektar.com. Having said that, I’d like to turn the call over to our President and CEO, Howard Robin. Howard?
Howard Robin
executiveThanks, Vivian, and I appreciate everyone being here today. As all of you are aware, several weeks back, we made public our intention to put in place a fresh strategic plan along with cost restructuring here at Nektar. And today I'm happy to share that we put that plan into action swiftly, and we'll start realizing continuous expense reductions beginning in Q3 of this year. With this new plan, our company gains a sharper focus on immunology and, just as importantly, it also stretches our cash runway out to at least the midpoint of 2026. One central piece of our refreshed pipeline strategy and plan involves pushing REZPEG forward, and our aim is to act fast to launch a well-powered, randomized Phase 2b trial of REZPEG in atopic dermatitis patients. We felt tremendous excitement about getting back the rights to this first-in-class regulatory T cell program from Lilly. Crucially, no royalties are due to Lilly for this handover, and REZPEG is now an asset wholly owned by Nektar. When it comes to atopic dermatitis as a target indication for REZPEG, we find it appealing for multiple reasons, especially because of how strong the data generated for REZPEG in atopic dermatitis patients has been. The landscape for non-topical biologic treatments is expanding considerably. This growth has been fueled by the approvals of DUPIXENT and other IL-13 based biologics. Within the U.S. by itself, roughly 16 million individuals live with atopic dermatitis, and 3 out of 4 of them deal with moderate to severe forms of the disease. Back in 2021, biologic sales for atopic dermatitis reached nearly $5 billion, and those sales keep climbing; even so, atopic dermatitis remains an area with a very significant unmet need for innovative biologic options. Most notably, the mechanisms patients can access today once topical treatments stop working overlap and fit into either IL-13 based mechanisms or JAK inhibitor. Efficacy is limited for both mechanisms, and each carries some noteworthy safety concerns, among them black box warnings associated with the JAK inhibitor class. Despite wider adoption of these mechanisms, at least 50% of patients show no response whatsoever to these therapies, and a number of patients experience their disease rebounding once they discontinue these therapies; this creates a genuine opening for REZPEG to arrive as the first regulatory T cell mechanism that stands apart from these overlapping existing mechanisms. The Phase 1b data for REZPEG was persuasive and laid the groundwork for us to assess the possibility of REZPEG becoming a remitted therapy offering longer-term disease control with maintenance dosing needed less often. In a few minutes, JZ will go over the data reported for REZPEG, covering the quality and durability of responses observed in patients. Now, as we noted in our reprioritization plan centered on immunology, we will additionally keep advancing our IL-15 program, NKTR-255 in cancer, as we look into strategic partnership possibilities. NKTR-255 is in development alongside cell therapies, and our view is that it may serve as a beneficial adjuvant treatment for businesses working in cell therapy. Our Phase 2 trial evaluating NKTR-255 together with the approved cell therapies BREYANZI and Yescarta, plus the Phase 2 JAVELIN Bladder Medley study with Mercy KGaA, will keep going as we look for a development partner. We still perceive substantial worth in NKTR-255, and early data demonstrated its potential as an enhancer of cell therapies that might help patients battling cancers that are very hard to treat. Finding a strategic co-development partner within this year is what we aim to do. As I mentioned before, immunology is where our main attention lies. Toward that aim, we have 2 preclinical candidates moving ahead: a TNFR2 antibody program and a PEG CFS 1 program, which JZ will go over shortly. For at least 1 of these programs, our objective is to have an IND ready in 2024; we feel deep gratitude toward our employees for their commitment and dedication to Nektar and to the patients we seek to serve. The choices made over the past month to cut our head count further were not easy, but we think they are the correct ones to maximize the success of REZPEG and our immunology programs; we are confident that concentrating on immunology is the best route forward to deliver important potential therapies to patients and to generate value for our shareholders; and now I'll hand the call to JZ so he can review the programs in greater detail.
Jonathan Zalevsky
executiveThanks, Howard. Let's begin with REZPEG. It's a distinctive molecule that, when used alone, has demonstrated encouraging efficacy across several clinical trials. What we're aiming for with this program is to tackle the fundamental Treg shortages and the resulting excessive activity of effector T cells seen in these conditions, by activating and growing Tregs in a selective manner. In the clinic, REZPEG stands out as the most advanced IL-2-based Treg mechanism, with potential and opportunity across a range of autoimmune disease indications. . Howard already mentioned 1 of those indications, atopic dermatitis. There are a few primary objectives when managing atopic dermatitis. Objective number one is treating the acute phase of the plant swiftly and effectively. And then the next point: when you look at the long run, getting a chronic condition under control proves much harder; plus, because most people who have moderate to severe forms of it need to take medicine for a great many years, a robust safety profile is also hugely important. When it comes to those with moderate to severe disease who need systemic treatment, what's available right now consists of two primary categories of drugs that have won approval and are considered standard of care at present. The initial category works against specific cytokines that propel the TH2 inflammation pathway — DUPIXENT, also called dupilumab, leads in this space, and it interferes with the IL-4 and IL-13 pathways. Lebrikizumab, anticipated to gain approval before this year ends, plus Adbry, which was approved not long ago, both aim at and obstruct IL-13 exclusively. DUPIXENT has been a very successful medication, but we now have real-world data showing where it falls short. One real-world evidence study indicates that lasting effectiveness isn't there: among patients who discontinued DUPIXENT, 79% saw their disease control slip away after roughly 4 months on average, and they had to begin treatment again. A different real-word study showed that 27% of patients taking DUPIXENT got moderate to severe conjunctivitis, requiring either anti-inflammatory eye drops or doctor visits. JAK inhibitors make up the other major category of atopic dermatitis treatments; they work by interfering with T cell activation, and through that mechanism they reduce inflammation in the dermis. JAK inhibitors produce striking results in atopic dermatitis, but they carry several black-box warnings, which reduces their attractiveness for long-term use. Because JAK inhibitors come with a number of safety concerns, the FDA's approved label limits them to people whose disease isn't well managed by other systemic drugs, biologics included. In practice, those boxed warnings lead dermatologists to conclude that JAK inhibitors won't work for a large share of their patients — among them anyone over 65, or those dealing with the conditions linked to that warning. Just like with DUPIXENT, when patients quit JAK inhibitors, they tend to lose control of their disease quickly and relapse. IL-13 blockers and JAK inhibitors each shut down their own pathway, but REZPEG was designed differently: it aims at the IL-2 receptor complex, driving Treg cell expansion and function. These cells then work to restrain the damaging T cells responsible for atopic dermatitis's fundamental disease process. Rather than simply interfering with effector cells, REZPEG aims to restore the immune system to a state of balance by increasing T-reg cells. Consequently, REZPEG operates via a mechanism of action completely unlike that of every other therapy currently approved or being developed for atopic dermatitis. Findings from the Phase 1b portion of our initial proof-of-concept study in moderate-to-severe atopic dermatitis give us greater confidence in REZPEG. In this 12-week Phase 1b trial conducted by Lilly, participants received either placebo or one of two REZPEG doses, after which they were followed for another 36 weeks once their last treatment dose was given. During last September's call, we provided interim results from this study. Among the participants, REZPEG led to a reduction in eczema area and severity index scores—referred to as the ES score—that depended on the dose, and by week 12, at the highest dose examined, scores fell by approximately 70%. At the same 12-week treatment point, we also saw improvements tied to dose in both the investigator global assessment for atopic dermatitis and the rates of itch response. Consistent with how REZPEG works, total Tregs as well as CD25bright Tregs increased relative to placebo by week 12. The effectiveness observed after 12 weeks of REZPEG treatment is in line with what has been seen following 16 weeks of DUPIXENT treatment. Still, the standout finding from that trial, without question, involved those individuals evaluated at week 36, which came after we had halted REZPEG administration. Their skin scores, along with other disease activity measures, stayed remarkably low. You simply don't see that kind of effect with DUPIXENT. Because of this, both our team and KOLs feel tremendous excitement regarding the possibility of durable responses and maintenance treatment given only occasionally when REZPEG is used for atopic dermatitis. Eli Lilly has now provided us with the study's final data, and those results build favorably upon the interim findings we shared earlier. On top of that, the dataset contains further efficacy endpoints that last year's EADV presentation did not address. I'll quickly go over a few of these points. First, among individuals given REZPEG, we saw a reduction in the percentage of body surface area affected by atopic dermatitis—what's referred to as BSA—and that reduction depended on dose. Those receiving the top dose achieved a 72% drop in BSA by week 12. Keep in mind that BSA is a continuous measure tied to EASI. We also saw dose-dependent decreases in two measures reported by patients: the Dermatology Life Quality Index, or DLQI, and the patient-oriented eczema measure, or POEM. Beyond that, the final data set includes information on a greater number of patients who made it through the 36-week observation period. The data from this study has us quite enthusiastic. REZPEG demonstrated effectiveness on every metric of disease activity as reported by physicians, as well as on outcomes reported by patients. What's more, those effects held up and persisted once patients ceased receiving REZPEG at week 12. We're eager for the conclusion coming in the next few months. At Nektar, when we set out to develop REZPEG, our thinking was that bringing Treg populations back to normal in autoimmune disease patients could rebalance the immune system and maybe deliver a therapy that modifies the disease itself. The prolonged sustained response observed in the atopic dermatitis study is something that makes us incredibly excited, because it matches up with our original hypothesis. Taken together, these results show that REZPEG could work as a remit of therapy, and they justify pushing REZPEG rapidly ahead into a Phase 2b trial in atopic dermatitis before this year is over. At this point we're putting the finishing touches on that Phase 2b study, and it will follow the design that the industry treats as standard for Phase 2 — much like the Phase 2 work done for approved IL-13 agents and other drugs; it will let us test several dose regimens of REZPEG across a 16-week induction phase, after which comes a 28-week maintenance phase; our belief is that this design will make the data easier to compare against earlier Phase 2 studies, with a primary endpoint readout at 16 weeks, once the induction phase wraps up. A scientific steering committee has been put together for this trial, and we're happy to share that Dr. Jonathan Silverberg of the George Washington University School of Medicine and Health Sciences is going to serve as its Chair. REZPEG's promise as a first-in-class Treg stimulator has us genuinely enthusiastic, and we can't wait to launch this Phase 2b study in patients suffering from moderate-to-severe atopic dermatitis within this year.
Jonathan Zalevsky
executiveEarlier this year, we shared Phase 2 top line results from the lupus trial. Those results demonstrated improvements that were clinically meaningful compared with placebo on important secondary endpoints, including BICLA and LLDAS at the middle dose. After we released that data, we took the opportunity to speak with numerous experts in lupus. Their response to what we found was favorable, and they shared a great deal of perspective. In those conversations, the key points these experts raised were the speed at which REZPEG generated BICLA and LLDAS responses, along with how large the treatment effect was on those measures. Everyone agrees that what we have from Phase 2b is sufficient to support building a Phase 3 registrational trial focused on these endpoints that could gain approval. Lupus is still something we're quite interested in—but just so it's clear, the atopic dermatitis Phase 2b trial comes first in our priorities, since running it as a randomized study lets us get to a definitive answer quickly. After we have data from that atopic dermatitis trial, there may be a chance for us to take another look at how we'd develop in lupus. Having REZPEG as a fully owned piece of our pipeline has us genuinely thrilled. Our immediate attention is on atopic dermatitis, yet our belief that REZPEG could have wide-ranging potential across many indications hasn't changed. As this program moves forward in development, we'll keep assessing additional opportunities and indications for REZPEG. Now on to NKTR-255. While we keep running our NKTR-sponsored Phase 2 trial of NKTR-255 alongside cell therapies, plus the Phase 2 JAVELIN Bladder Medley Study together with Merck KGaA, our partner, we're also looking at strategic partnership possibilities for this asset. NKTR-255 works by engaging the entire biology of the IL-15 pathway, delivering functional activation and homeostatic regulation of IL-15 responses in immune cells — primarily natural killer cells, CD8 T cells, and immune memory subsets. Because it acts as a full agonist of the IL-15 pathway, it's able to signal via both cis and trans presentation of the TRIMERIC-IL-15 receptor complex. NKTR-255 has the potential to be paired with a variety of approaches — targeted therapies, cell therapies such as CAR-T and TCR treatments, and checkpoint inhibitors — with the aim of boosting how well those agents work. We still believe this program holds substantial worth, since NKTR-255 demonstrates wide possible use across oncology indications. Even so, we think that putting our immunology programs first gives us a strong chance to build value for our shareholders. As a result, we see advancing NKTR-255 alongside a strategic partner as the optimal route for this program, and we intend to secure such a partner during this year. Given these changes in priorities, our NKTR-255 trial testing it alongside DARZALEX FASPRO for multiple myeloma, and alongside cetuximab for solid tumors, is being brought to a close, since we're now putting greater emphasis on the cell therapy work at bladder cancer sites. Moving on to what we're doing before the clinic, we're pushing our research pipeline forward, centered on autoimmune disease. The initial effort here involves our newly developed PEG colony-stimulating factor, which we also call the CSF1 program. This PEG CSF1 is a form of the CSF1 protein that's been altered using polyethylene glycol, or PEG. We engineered this molecule to carefully adjust both its receptor interaction and its exposure, allowing it to selectively control the mechanisms that settle inflammation. From where we stand, this particular program has potential applicability in a wide range of therapeutic areas — acute inflammation, chronic inflammation, and fibrosis among them. We're also very excited about moving this program forward at a faster pace. Our second preclinical candidate is the TNFR2 agonist antibody, a program we're advancing in partnership with Biologic Design. Tregs, neuronal cells, and endothelial cells all show elevated TNFR2 expression, and it has been shown that agonism at TNFR2 boosts the suppressive function and broader functional profile of Tregs. A lack of it is tied to CNS autoimmunity. At the same time, when it is present, protective benefits have been associated with neuronal cells, as well as additional cell populations and tissues elsewhere in the body. Our discovered lead antibodies show binding and signaling that's selective within Tregs, which allows us to create them with autoimmune disease specifically in mind. This program has us very excited, along with its potential to reduce inflammation and bring about resolution in patients. For at least one of these programs, we plan to file an IND at some point in 2024, and we look forward to updating you as they move forward. Having said that, I'll now pass the call to Sandy, who will cover the plan for restructuring costs as well as our financial guidance.
Sandra Gardiner
executiveThank you, JZ, and good afternoon to all of you. To begin, I want to walk through what we're doing right now in Q2 under the cost restructuring plan aimed at bringing operating expenses down. After that, I'll share our financial guidance for 2023. We closed out the first quarter with roughly $457 million in cash and investments, and our balance sheet carries no debt. As was announced back in April, we've cut our San Francisco-based workforce by around 60%. Restructuring-related costs will be settled by the close of June, during the second quarter. Going forward, we have about 55 employees located in San Francisco. Measured on an annual run rate basis, the personnel reduction translates to roughly $30 million per year in lower operating expenses. Quarterly savings will start in Q3 of 2023, and we anticipate realizing the full annual benefit in 2024. With these cuts to yearly operating expenses, as Howard mentioned, our plan gives Nektar a cash runway extending through at least the middle of 2026, based on the cash we currently hold. Any cash generated through partnering or other strategic activities would stretch that runway further and strengthen the balance sheet. Before turning to 2023 financial guidance, I want to flag a few non-cash items booked during the first quarter of 2023. First, we took a one-time non-cash charge of $76.5 million to impair goodwill that had previously been recorded on our balance sheet, mostly tied to two acquisitions completed over 17 years ago — the 2001 purchase of Share Water Corporation and the 2005 purchase of Aerogen. In Q1, we also booked a $13.2 million noncash impairment, primarily for leased assets. Together, these non-cash impairment charges of $89.7 million added $0.48 to our net loss per share in Q1 2023. Setting aside those non-cash impairment charges, net loss on a non-GAAP basis for the first quarter of 2023 came to $47.3 million, or $0.25 basic and diluted loss per share. Now I'll go over our 2023 financial guidance. We expect to finish 2023 with no less than $315 million in cash and investments. During the second quarter of 2023, we'll make non-recurring cash payments of about $8 million tied to our head count reduction. We anticipate net cash usage will decline in the latter half of the year, once those payments are made in June. As I mentioned before, this lower net cash utilization pushes our cash runway out through at least the middle of 2026. Our GAAP revenue for the full year 2023 is projected to land between $80 million and $90 million. That revenue figure includes $65 million to $70 million in non-cash royalties plus $15 million to $20 million in product sales. Looking ahead to the whole of 2023, our GAAP R&D operating expenses should land somewhere in the range of $105 million to $115 million. That figure takes in roughly $15 million to $20 million in non-cash depreciation along with stock compensation expense. As for G&A operating expense across all of 2023, we're projecting a range of $75 million to $80 million, and that likewise includes about $15 million to $20 million in noncash depreciation plus stock compensation expense. Over the course of 2023, we anticipate recording restructuring, impairment and costs of terminated programs of roughly $30 million to $35 million, and $13.2 million of that amount is the non-cash impairment I referred to before, which was recognized during Q1 2023. Non-cash interest expense for the entirety of 2023 should come in at somewhere between $20 million and $25 million. Having said all that, we're ready to take questions. Operator?
Analyst
analystHello, and good afternoon to all. Charlie here, filling in for Chris. I really appreciate the chance to ask my questions. I get why everyone is enthusiastic about REZPEG returning to the company. Still, I wanted to ask: when we consider the restructuring work ahead, would you consider the possibility of eventually bringing in another pharma partner for REZPEG? Or would you rather keep it in-house right now? Then I have one short follow-up.
Howard Robin
executiveYes. Good. Howard speaking. That's a good question. Right now, I don't intend to partner with anyone else. This program belongs to Nektar. To me, it's a terrific opportunity for us to carry it all the way to completion. Looking at the data, I believe we can successfully finish a Phase 2b trial in atopic dermatitis; it would be the first mechanism of its kind and, I think, lay the groundwork for a new approach to treating autoimmune disease. So as things stand, it's our drug. I hope that clears it up.
Analyst
analystNo, that helps a lot. Thanks. And then, just briefly, when we consider the timeline for the Phase 2b in atopic dermatitis that just unfolded, should we anticipate that data around maybe a mid-2024 type of timeline?
Howard Robin
executiveYes. Look, we will — look, we will launch that trial as quickly as possible. Finalizing the design and getting sites up and running is going to require a few additional months. From the moment we begin, I'd say you're looking at roughly 14 to 18 months to finish that study. So the moment we get it started, everyone will receive a more comprehensive update.
Analyst
analystOkay. Great. Thanks a lot for fielding our questions.
Jerry Gong
analystHi, this is Jerry Gong, sitting in for Mara Goldstein. We appreciate you taking our questions. We've just got two quick ones. Regarding the Phase 2b atopic dermatitis trial, do you intend to run a differential analysis across patients based on prior DUPIXENT, JAK, or other cytokine exposure? And a quick one about NKTR-255: could you share any detail on what kind of partnership we might expect? For instance, would something along the lines of a Lilly deal be of interest?
Howard Robin
executiveWell, okay, let me address the second part first, and then I'll hand it to JZ for the first part of your question. I think, look, our focus — at this moment, I think we — our priority needs to be ensuring our cash runway extends through at least the middle of '26. I'm confident we can achieve that; and what that means is that right now we're going to concentrate on atopic dermatitis, since it's a huge market. Definitely far bigger than the cell therapy market. And I really believe that's where our attention belongs; and I think REZPEG holds potential not only for treating atopic dermatitis; but should we succeed there, the promise of that kind of mechanism across various autoimmune disorders is rather exciting. As for NKTR-255, I honestly can't say yet what that will look like. Clearly, it would be used alongside a cell therapy, whereas with REZPEG, obviously, what we're doing is active as a single agent. So we need to carefully explore what such a deal would involve. It might be a joint collaboration. It might be a license deal. I don't know yet. For sure, every cell therapy company is in discussions with us, because I genuinely believe they see IL-15 as important for potentiating cell therapies. So, plenty of discussion, plenty of potential; it could be a collaboration, it could be a license, I don't know yet.
Jonathan Zalevsky
executiveAlright, and hello Jerry. It's JZ here. So, regarding your initial question, we're currently finalizing the study design, though we still need to wait for feedback from the health authorities. However, I can share some detail. Our plan is to enroll roughly 280 patients. During the induction phase, we'll evaluate several dose regimens. Then, in the maintenance phase, we'll additionally be examining dosing schedules that are very infrequent. The rationale behind this design is essentially to build upon what we discovered in the Phase 1b study. There, we observed strong and long durability of effect, which we think in the maintenance arm could enable us to reach very, very low-frequency dosing, something that would be highly differentiating. I believe every other agent in this class needs either twice monthly or monthly dosing of that sort. As we move closer to later this year, nearer to launching the study, we'll provide another update where we'll reveal the study design, some key endpoints we're measuring, and all the other features. So please keep an eye out for that; it'll be arriving shortly.
Jerry Gong
analystThat's really useful. I appreciate the responses.
Analyst
analystHi there. Good afternoon, everyone. I'm JL, filling in for Jess. We've got a few questions. To start, regarding the strategic choice to bring in a partner for 255, I'm curious whether this is a recent development following your recovery of complete rights to REZPEG, or if it had always been a possibility for 255. Then, concerning your cash runway, could you provide any additional details to clarify things for us — for instance, does your present cash burn rate extend at least to mid-2023, with a budget that covers finishing the Phase 2b trial for REZPEG? Also, does that budget factor in your 255 trial with cell therapy in Phase 2, which I understand is currently ongoing? And I believe you just mentioned some new programs — how much runway have you allocated for those preclinical efforts, in case some of them advance into the clinic? Thanks so much.
Howard Robin
executiveAll right. Great. Those are excellent questions. Well, we were — well, throughout our work — as a company centered on immunology, a business focused on immunology, naturally 255 played a key part in our pipeline, and I continue to believe NKTR-255, IL-15 holds a significant role in immuno-oncology. Even so, we must concentrate, and we must concentrate on areas where the biggest opportunities exist and where we can pursue novel mechanisms, and that is REZPEG. So, will we continue developing 255? Yes; however, I want to — I do believe our perspective has shifted by now after recent years, and we've concluded that as an immunology-focused company, we want to secure a strategic partner for NKTR-255. That's to let us completely leverage our expertise in immunology. Turning to the latter part of your inquiry, our cash runway extending through at least '26 covers the entire expense of a 2b trial in atopic dermatitis. That whole expense is included, roughly $60 million. It's completely factored in there, along with the expense of advancing the NKTR-255 trials to attract a partner and the IND submission for those 2 programs; so, everything is captured in the runway through 2026. Should we pursue any additional deals or opportunities, that would simply extend — as Sandra mentioned before, that would simply extend how long our cash runway lasts. I trust that addresses it.
Analyst
analystHello. Mary Dryden here, filling in for Greg. We really appreciate you answering our questions. So, regarding the REZPEG program, how are those talks with regulators proceeding when it comes to developing REZPEG for atopic dermatitis? And perhaps, considering the entire program, which additional indications besides AD and lupus do you believe could gain from this therapy? Thanks.
Howard Robin
executiveAll right; excellent questions. I'll hand it to JZ so he can provide a solid response.
Jonathan Zalevsky
executiveRight. Thank you, Howard. Appreciate the question. The agency has, naturally, reviewed everything from all the studies submitted to date, which covers the Phase 1b trial in atopic dermatitis, and naturally there was protocol feedback along with numerous conversations with the FDA regarding that trial. Regarding the Phase 2b study, like I said before, we're in the process of finalizing its protocol. We'll be requesting feedback from the health authority on that protocol extremely soon. After that, we'll receive the further information that lets us lock down the protocol and launch the trial later in the year. As for how many indications we're looking at, REZPEG has so far been assessed across quite a few. There was activity observed in atopic dermatitis, which we've talked about. There was activity in a Phase 1b trial in psoriasis. We observed clinical activity in lupus. With ulcerative colitis, the trial began too early, so it wasn't efficacious for that indication; however, one thing this gives us is insight into a variety of different immunological contexts where we understand Tregs matter, and we understand that either Treg dysfunction or a missing Treg compartment that controls conventional or effector T-cells presents a challenge. So there's a variety of further indications we're considering. There are a number within the Th2 spectrum of diseases. Clearly, atopic dermatitis is a subject here. There are many other atopic conditions affecting other organs that are absolutely something we're thinking about a great deal. There are certain neuroinflammatory diseases we consider as well, plus others. So there's certainly an extremely broad spectrum, both biologically and with this novel mechanism, for considering multiple indications. As we restated during the call, and as Howard just noted, focus matters critically; therefore, beyond concentrating on our immunology pipeline, we're prioritizing our Phase 2b trial in atopic dermatitis. But as we advance that trial and as data emerges from it, we anticipate that down the road we'll also be expanding the program.
Analyst
analystOkay, thanks a lot.
Daina Graybosch
analystHello, and thanks for asking. I want to get a sense of how you view REZPEG's therapeutic window. More specifically, within the lupus trial, there was also a dose response when it came to tolerability or safety. And the top dose, I believe, is near the level at which you observed the largest Treg increases and efficacy in AtD, yet it appears fairly intolerable in lupus. So in your Phase 2b, how are you handling that? Thanks.
Howard Robin
executiveWell, I will hand it to JZ for a fuller explanation, but these effects — a Treg mechanism's impact differs somewhat across diseases. And JZ, would you like to add anything on that?
Jonathan Zalevsky
executiveYeah. Thank you, Daina, for asking that. With even low-dose IL-2, we've observed — and I'm aware you know the literature well — that its behavior differs depending on which disease indication you're looking at. The sensitivity of the underlying immune dysfunction also varies, as does the way low-dose IL-2 acts. One lesson that came out of the lupus patient study is this: the high dose, which we'd previously examined across many settings — from healthy volunteers to mild lupus patients, psoriasis patients, atopic dermatitis patients, and ulcerative colitis patients — didn't really produce systemic toxicities or problems at that dose level in those other populations. In moderate to severe lupus patients, though, we saw greater intolerability. So one hypothesis we hold relates to what the disease itself is like. Lupus patients have a much more systemic Th1 disease, while atopic dermatitis is different — it's a Th2 type of disease. So despite the same dose level being tested in both populations, the profiles we saw were clearly quite different, both for efficacy at that dose level and for tolerability. What gives us comfort as we move ahead in the atopic dermatitis Phase 2b study is that we've already tested that same dose level — 24 micrograms per kilogram — in the Phase 1b, which is basically analogous to the 1,800-microgram flat dose. That dose level has already been examined in the Phase 1b study. When we look at the efficacy profile alongside the tolerability profile, it appears to be a quite reasonable and encouraging, perhaps even positive, risk-benefit profile from that small study; so we're comfortable continuing with that dose level in atopic dermatitis patients. Ultimately, it comes down to a difference in patient population and disease indication. That's really not unusual for a great many drugs.
Daina Graybosch
analystAll right. Thanks.
Analyst
analystHello. My name is Hans, filling in for Boris Peaker. We appreciate you answering our questions. One is about REZPEG. When the choice was made to hand that asset back, I'm curious whether you might share a bit of detail on what drove that. Also, you mentioned receiving some input — favorable input — from key opinion leaders? Why does that leave you feeling assured about proceeding with this step?
Howard Robin
executiveOkay. Fine. That's definitely a solid question, and quite fair. See, Lilly has different things it's prioritizing in atopic dermatitis; and once we brought the REZPEG data, covering both lupus and atopic dermatitis, before those various key opinion leaders, all of the key opinion leaders who went through that data felt REZPEG is a therapeutic with promise that ought to be moved ahead in the clinic to benefit patients. Thus, I'd say we felt quite at ease when we approached a few of the genuine thought leaders in atopic dermatitis along with the genuine thought leaders in lupus and got them to examine the data. They actually came away quite impressed by it. Regarding Lilly, we were extremely pleased to receive REZPEG back from them. My view is they reached a commercial conclusion that fails to capture REZPEG's intrinsic worth. Rather, it genuinely mirrors their strategic path, in which REZPEG could have become a possible rival to their other atopic dermatitis therapy — one they expect to have approved before long — so I believe many factors explain why they returned it to us; yet I would not count insufficient efficacy for the drug among them. I trust that addresses what you asked.
Analyst
analystThanks. That helps a lot. For my second question, it's more of a broad one. Now that your company is moving toward immunology people in biotech, what steps have you taken within your organization — in terms of know-how — to enable that shift or make it succeed?
Howard Robin
executiveAll right. Because JZ oversees that area of the company, I'll have him take that one. Go ahead, JZ.
Jonathan Zalevsky
executiveRight; so over time, we've added personnel who know a lot about finding new drugs as well as advancing them, specifically for immunology conditions. So that's something we've actually been doing; and after that, whenever we run into either a skill shortfall or some other kind of hole, then clearly we seek assistance, the way other folks do, from external specialists who assist in strengthening certain choices and thinking of ours. On top of that, as a whole, inside the group responsible for building the pipeline, there's an enormous amount of experience spanning work in immunology areas across numerous illnesses and numerous sorts of immunology contexts. And that spans lots of organizations and especially big pharma, where considerable know-how existed within the firm. Thanks.
Analyst
analystThanks.
Howard Robin
executiveWonderful. I appreciate all of you being here with us today. Once more, my gratitude goes out to our team members for their dedication and attention during a stretch of tough and trying circumstances, the kind it appears everyone in biotech is facing currently. We're eager to tell all of you about how REZPEG is advancing, so keep watching for updates. This molecule, in my view, holds substantial promise. Many thanks.
Operator
operatorThat brings us to the end of this conference call. We appreciate everyone taking part. You’re free to disconnect at this point. Have a great day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.